A Game-Changer for Public Health? The FDA Eyes a Bold New Path for Vaccine Approval
A Whisper Becomes a Roar: Unpacking the Turmoil at FDA's Biologics Hub
A New Chapter: Peter Marks, Former FDA Vaccine Czar, Lands at Eli Lilly